California Department of Public Health

Alzheimer’s Disease Program

November 8, 2017

Presented to California Health and Human Services Agency

Olmstead Advisory Committee

Caroline Peck, MD, MPH, FACOG
Chief, Chronic Disease and Injury Control Division

Terence Kelley, M.S. HCA
Program Lead, Alzheimer’s Disease Program
What is Alzheimer’s disease?

Alzheimer’s disease is a degenerative brain disease and the most common cause of dementia (Wilson et al., 2016).
Other Causes/Types of Dementia

- Cerebrovascular Disease/Not Vascular Dementia
- Parkinson’s Disease
- Normal Pressure Hydrocephalus
- Progressive Supranuclear Palsy
- Depressive Mood Disorder
- Alcohol Abuse or Dependence
- Drug Abuse or Dependence
- Medication (toxic effect or metabolic derangement)
- Metabolic Disorder
- Toxin
- CNS Infection
- Space-occupying Lesion
Alzheimer’s Disease Program

The State of California provides administrative oversight for:

- ten California Alzheimer’s Disease Centers (CADCs)
  - Diagnosis and treatment of patients
  - Education and training of professionals
  - Evaluation of the ten Alzheimer’s Disease Centers

- Alzheimer’s Disease Research Tax Check-Off Fund
  - Provision of more than $22 million in research funds to university researchers, medical centers, health systems, and others.

The California Alzheimer's Disease Program was established pursuant to Assembly Bill 2225 (Felando, Chapter 1601, Statutes of 1984) and was expanded pursuant to Senate Bill (SB) 139 (Mello, Chapter 303, Statutes of 1988).
California Alzheimer’s Disease Center Locations

• UC Davis – Sacramento
• UC Davis – Walnut Creek
• UC San Francisco
• UC San Francisco – Fresno
• Stanford University

• UC Los Angeles
• USC
• USC – Rancho Los Amigos
• UC Irvine
• UC San Diego
California Alzheimer’s Disease Center
Primary Diagnoses

CADCs Dementia Primary Diagnosis, 2015-2016

- Possible AD: 38%
- Probable AD: 21%
- Mixed Diagnoses: 15%
- Diagnosis Undetermined: 4%
- Other: 2%
- Probable DLB: 3%
- Possible DLB: 4%
- Probable IVD: 2%
- Possible IVD: 3%
- Frontal Temporal Lobe Degeneration: 0%
- Progressive Supranuclear Palsy: 0%
- Depressive Mood Disorder: 1%
- Head Trauma: 1%
- CVD/Not Vascular Dementia: 1%
Senate Bill 613
(Allen, Chapter 577, Statutes of 2015)

• Required CDPH to convene a multidisciplinary expert workgroup to update the 2008 Guideline for Alzheimer’s Disease Management (Guideline).

• On June 29, 2016: the Program, in partnership with the Alzheimer’s Association, conducted the workgroup comprised of stakeholder experts in Alzheimer’s disease.

• The updated Guideline aligns with:
  – The “Let's Get Healthy California” Task Force Report (Goal 2. Living Well: Preventing and Managing Chronic Disease)
  – The California Wellness Plan, 2014 (Objective 2.4.1S)
Let’s Get Healthy
California Task Force Framework

The Triple Aim:
Better Health • Better Care • Lower Costs

Health Across the Lifespan

Living Well:
Preventing and Managing Chronic Disease

Healthy Beginnings:
Laying the Foundation for a Healthy Life

End of Life:
Maintaining Dignity and Independence

Pathways to Health

Redesigning the Health System:
Efficient, Safe, and Patient-Centered Care

Creating Healthy Communities:
Enabling Healthy Living

Lowering Cost of Care:
Making Coverage Affordable and Aligning Financing to Health Outcomes

Health Equity: Eliminating Disparities
Guideline

- 4th edition of the California Alzheimer’s Clinical Care Guideline
- 4 Primary Topic Areas:
  - Assessment
  - Care Plan
  - Education and Support
  - Important Considerations
Guideline

Assessment
– Understand (or know) the patient, by addressing the patient directly and by monitoring and reassessing changes.

Care Plan
– Include beneficial interventions such as disease management, treat emotional, behavioral and/or mood symptoms, evaluate safety issues, document goals of care, promote healthy living, refer to clinical studies

Education and Support
– Connect with social and community support

Important Considerations
– Include time sensitive issues such as advance planning, capacity evaluation, elder abuse, driving and eligibility for benefits
Alzheimer’s Disease and Its Impact

Alzheimer’s Disease is the Most Common Form of Dementia and It Disproportionately Impacts Many Californians. Dementia is a general term for memory loss and other impairments serious enough to interfere with daily life. Alzheimer’s accounts for 50 to 80 percent of dementia cases and currently impacts an estimated 600,000 Californians, a number projected to grow to 840,000 by 2025. Alzheimer’s is the 6th leading cause of death in California and the only condition in the top 10 without a known cause, cure, or prevention.

More women than men have Alzheimer’s disease and other dementias such as vascular dementia and dementia with Lewy bodies, among others. Almost two-thirds of Americans with Alzheimer’s are women, as are the majority of family caregivers. Older African Americans and Hispanics are more likely than older whites to have Alzheimer’s disease and other dementias with African Americans at twice the prevalence rate and Hispanics one and one-half times the rate.

This 2017 Update Reflects New Evidence, Improved Practice and Changes in Law — This is the 4th edition of the California Alzheimer’s Clinical Care Guideline, first published in 1998 and revised in 2002 and 2008. The 2017 update specified in statute (SB 613, Chapter 577, 2016) addresses changes in scientific evidence, clinical practice, and state and federal law. Changes include:

NEW GOVERNMENT POLICIES

Medicare Reimbursement — The Centers for Medicare & Medicaid Services (CMS) now reimburses physicians for annual wellness visits every 12 months and includes payment for a Health Risk Assessment, including reimbursement for a cognitive screen. Medicare will pay for cognitive and functional assessments and care planning for patients with Alzheimer’s disease and other cognitive impairments.

Adoption of Physician Order for Life Sustaining Treatment (POLST) — The POLST form gives patients more control over their end-of-life care, including medical treatment, extraordinary measures (such as a ventilator or feeding tube) and cardiopulmonary resuscitation. POLST can prevent unwanted treatments, reduce patient and family suffering, and ensure a patient’s wishes are honored.

Social Security Grant Compassionate Allowance Benefit for Early-Onset Individuals — Individuals under age 65 diagnosed with Alzheimer’s disease are eligible for the Social Security Compassionate Allowance benefit with minimal objective medical information provided by a physician.

Healthy Brain Initiative — The Centers for Disease Control and Prevention has mapped out a strategy for state and national partnerships through The Healthy Brain Initiative, emphasizing proven public health strategies such as monitoring and evaluation, education and training, policy development, and workforce competencies.

EMERGING PRACTICE TRENDS

Emphasis on Early Detection, Early Diagnosis and Mild Cognitive Impairment — Mild cognitive impairment can cause serious cognitive changes noticed by those individuals who experience changes or by other people, but not severe enough to interfere with daily life or independent function. As with other chronic diseases, public health experts are focusing on possible early interventions to delay the onset and slow the progression of Alzheimer’s disease.

New Evidence About Antipsychotic Medications and FDA Black Box Warning Labels — In April 2005, the U.S. Food and Drug Administration (FDA) notified health care professionals that both conventional and atypical antipsychotics are associated with an increased risk of mortality in elderly patients treated for dementia-related psychosis. The FDA notified health care professionals that patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death. Since issuing that notification, the FDA has reviewed additional information that indicates the risk also is associated with conventional antipsychotics.

Gaps in Disclosure and Documentation — Scientists who studied patient surveys and Medicare claims data discovered only 45 percent of those billed for Alzheimer’s-related care were told by their doctors of their disease. Overlooking or avoiding diagnosis impedes care and denies access to needed services. In an era of electronic health records, documenting the diagnosis is critically important in order to deliver person-centered care.

Lifestyle Modifications — Some risk factors for dementia, such as age and genetics, cannot be changed, but the brain can be protected by some of the same strategies that guard against cardiovascular risk, including smoking cessation; keeping blood pressure, cholesterol and blood sugar within recommended limits; and, maintaining a healthy weight. Regular physical exercise may help lower dementia risk. Diet may impact brain health through its effect on heart health. Evidence suggests heart-healthy eating patterns, such as the Mediterranean diet, which emphasizes eating foods like fish, fruits, vegetables, beans, high-fiber breads and whole grains, nuts, and olive oil may help protect the brain.
Alzheimer’s Clinical Care Guideline

ASSESSMENT

Address the Patient Directly
- Confirm, disclose and document the diagnosis in the patient record.
- Identify the patient’s culture, values, primary language, literacy level, and decision-making process.
- Identify the primary caregiver and assess the adequacy of family and other support systems, paying attention to the caregiver’s own mental and physical health.

Understand (or Know) the Patient
- Monitor and Reason Out Changes
  - Upon sudden changes or significant decline, and at least annually, conduct and document the following:
    - Ability to manage finances and medications, as well as daily functions, including feeding, bathing, dressing, mobility, toileting and convenience;
    - Cognitive status, using a valid and reliable instrument, e.g., MoCA (Montreal Cognitive Assessment), AD8 (Acronym Dementia 8) or other tool;
    - Comorbid medical conditions which may present with sudden worsening in cognition and function or changes in behavior, and could complicate management of dementia;
    - Emotional, behavioral and/or mood symptoms;
    - Medications, both prescription and non-prescription, for appropriate use and contraindications; and
    - Adequacy of home environment, including safety, care needs, and abuse issues.

CARE PLAN

Disease Management
- Discuss the progression and stages of the disease.
- Evaluate and manage comorbidities in context of dementia and progress.
- Consider use of cholinesterase inhibitors, N, methyl-D-aspartate antagonist, and other medications, if clinically indicated, to slow cognitive decline.
- Promote and refer to social services and community support.

Beneficial Interventions
- Treat Emotional, Behavioral and/or Mood Symptoms
  - First consider non-pharmacologic approaches such as counseling, environmental modification, task simplification, activities, etc.
  - Consult with or refer to mental health professionals as needed.
  - If non-pharmacologic approaches prove unsuccessful, THEN use medications targeted to specific emotions, behaviors or moods, if clinically indicated. Note, many medications carry an FDA black box warning and side effects may be serious, significant or fatal.

Evaluate Safety Issues
- Discuss driving, wandering, falls, fire hazards, etc. Recommend medical identification for patients who wander.

Document Goals of Care
- Explore preferred intensity of care to include palliative care and end-of-life options such as hospice.
- Provide information and education on advance health care directives, Do Not Resuscitate Orders, Physician Orders for Life-Sustaining Treatment, Durable Power of Attorney and other documents.

Promote Healthy Living
- Discuss evidence in support of modifiable risk factors, e.g., regular physical activity and diet/ nutrition.

EDUCATION AND SUPPORT

Connect with Social and Community Support
- Involve the patient directly in care planning, treatment decisions and referrals to community resources.
- As the disease progresses, suggest appropriate home and community-based programs and services.
- Link the patient and caregiver to support organizations for culturally appropriate educational materials and referrals to community resources.

Engage with the Community

For statewide patient and family resources, link to:
California Department of Public Health,
Alzheimer’s Disease Program
(916) 552-9800
Alzheimer’s Disease Program
Check for local services in your area.

IMPORTANT CONSIDERATIONS

Advance Planning
- Discuss the importance of basic legal and financial planning as part of the care plan and refer for assistance.

Capacity Evaluations
- Assess the patient’s decision-making capacity and determine whether a legal surrogate has been or can be identified.
- Consider literacy, language and culture in assessing capacity.

Time Sensitive Issues

Eligibility for Benefits
- Patients diagnosed with early-onset Alzheimer’s disease may be eligible for Social Security Compassionate Allowance.
- Other benefits may include Department of Veterans Affairs or long-term care insurance coverage under existing policies.
Guideline

- The ten California Alzheimer’s Disease Centers will use this updated guideline for education of primary care physicians and residency training programs.

- It is intended to help primary care physicians and physician extenders offer comprehensive care to patients with Alzheimer's disease.
Guideline - Dissemination

• Online at the CDPH California Alzheimer's Disease Program website located at:
  https://www.cdph.ca.gov/Programs/CCDPHP/DCDIC/CDCB/Pages/AlzheimersDiseaseResources.aspx and
  http://www.caalz.org/2017%20Guideline%20FINAL%20RELEASE.pdf

• The Alzheimer’s Association held a meeting in May 2017 disseminate the Guideline to a variety of professional trade associations and held a press conference with Dr. Charles DeCarli, M.D. Director of the Alzheimer’s Disease Center at UC Davis.

• The Medical Board of California published the Guideline in the Summer 2017 Newsletter.
Guideline – Dissemination

• The Alzheimer’s Disease Program is currently working with the Federal Agency for Healthcare Research and Quality (AHRQ) to have the Guideline submitted to the National Guideline Clearinghouse.
Guideline – Dissemination

• The Alzheimer’s Disease Program is currently working with the Physician Consortium for Performance Improvement (PCPI) to incorporate part of the Guideline into a recommended National Quality Forum clinical quality measure used by the Center for Medicaid and Medicare Services (CMS).
Early Detection and Diagnosis Update

• Senate Bill 833
  – Amended Section 125281 of the CA Health and Safety Code and allocated $2.5 million from the CA Budget Act of 2016 to each of the ten California Alzheimer’s Disease Centers
  – Legislation sponsored by the Alzheimer’s Association
  – The entire 2.5 million from SB 833 was evenly distributed to all ten Centers
Early Detection and Diagnosis Toolkit

• Purpose:

“The purpose of this toolkit is to enable accurate diagnosis of dementia due to Alzheimer’s disease in a primary care setting, and to help clinicians identify situations where diagnosis of Alzheimer’s disease is not straightforward and help make appropriate referrals.”
Early Detection and Diagnosis Toolkit

- Why Early Detection and Diagnosis?
- The toolkit is intended for the general clinical practice setting.
Early Detection and Diagnosis Toolkit

• General Principles:
  – The design of this toolkit is based on several principles, all of which are addressed by specific components of the toolkit.
Early Detection and Diagnosis Toolkit

- The toolkit will contain the following elements:
  - Principles of the Underlying Toolkit
  - Wellness Check/Identification of Significant Cognitive Complaints
  - Full Assessment: History and Physical Exam
Early Detection and Diagnosis Toolkit

• The toolkit will contain the following elements:
  – Lab and Imaging Assessment
  – Counseling
  – Billing Guidance
Questions?

Caroline Peck, MD, MPH, FACOG
Chief, Chronic Disease and Injury Control Division
California Department of Public Health
California Chronic Disease Director
916) 552-9940 or 916 449-5700
caroline.peck@cdph.ca.gov

Terence Kelley, M.S. HCA, Program Lead
Alzheimer’s Disease Program
California Department of Public Health
(916) 552-9952
terence.kelley@cdph.ca.gov

Website: Alzheimer's Disease Program
https://www.cdph.ca.gov/Programs/CCDPHP/DCDIC/CDCB/Pages/AlzheimersDiseaseProgram.aspx